Scientists around the world are racing to develop a vaccine for COVID-19. But experts have said it could take a year to 18 months for one to hit the market. The process for testing and approving a vaccine is long and complicated.
That can be frustrating when the coronavirus is taking more and more lives every day. But cutting corners to push a vaccine through faster can lead to devastating consequences. We know that, because it’s happened before.
Facing shortages of critical equipment, medical workers must make life-or-death decisions about who receives care. WSJ’s Joe Palazzolo reports from an emergency room that’s running short on ventilators, and Chris Weaver explains the plans hospitals are putting in place to decide who gets them.
Arthur Caplan, a bioethicist at NYU’s School of Medicine, talks about how hospitals think about these difficult choices.
On the Mayo Clinic Q&A podcast, Dr. Jessica Lancaster, a Mayo Clinic immunologist, discusses aging and the immune system. Some people are at higher risk of getting very sick from COVID-19 because of their age or underlying health conditions, according to the Centers for Disease Control and Prevention (CDC).
Adults 60 and older and those with an underlying health condition or a compromised immune system appear to develop serious illness more often than others. This interview was recorded March 19, 2020.
Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
From Wall Street Journal article:
Our experience suggests that hydroxychloroquine, with or without a Z-Pak, should be a first-line treatment. Unfortunately, there is already a shortage of hydroxychloroquine. The federal government should immediately contract with generic manufacturers to ramp up production. Any stockpiles should be released.
As a matter of clinical practice, hydroxychloroquine should be given early to patients who test positive, and perhaps if Covid-19 is presumed—in the case of ill household contacts, for instance. It may be especially useful to treat mild cases and young patients, which would significantly decrease viral transmission and, as they say, “flatten the curve.”
Global health officials have praised China and South Korea for the success of their efforts to contain the coronavirus. What are those countries getting right — and what can everyone else learn from them?
Stocks tanked again as the outbreak was officially declared a pandemic and policies to address its impact proved lacking or ineffective.
All flights to the U.S. have been suspended from Europe. Many schools announced they would close indefinitely, some nursing homes banned visitors, and workplaces across the country have urged their employees to work from home. Here are the latest updates.
Drug Pricing Theme Issue: Is Pharma Earning Too Much?, R&D Costs Required to Bring a New Drug to Market, Probiotic Safety, and more
One in 4 people in the US has difficulty paying the cost of their prescription medications. This stark fact was recently reported in a 2019 Kaiser Family Foundation public opinion poll among a nationally representative random sample of 1205 adults.1 Persons who reported having the greatest difficulty affording their prescription drugs were those who most needed them, including those who took 4 or more prescription drugs, spent $100 or more per month on their drugs, and reported being in fair or poor health.